Vaxxinity, Inc.
🇺🇸United States
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05762276
- Locations
- 🇦🇺
Emeritus Research, Melbourne, Victoria, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺University of the Sunshine Coast (USC), Morayfield, Queensland, Australia
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05477095
- Locations
- 🇧🇪
Katholieke Universiteit Leuven, Leuven, Belgium
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 944
- Registration Number
- NCT05293665
- Locations
- 🇺🇸
PanAmerican Clinical Research, Brownsville, Texas, United States
🇵🇭Health Index Multispecialty, Bacoor, Philippines
🇵🇭Iloilo Doctors Hospital, Iloilo City, Philippines
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Vaxxinity, Inc.
- Registration Number
- NCT04683224
© Copyright 2024. All Rights Reserved by MedPath